Skip to main content

Table 2 Pidotimod: clinical trials in adults

From: Pidotimod: the state of art

Study Population Clinical outcome Laboratory outcome
Evaluation of the efficacy of Pidotimod in the exacerbations in patients affected with chronic Bronchities 181 COPD ↓Frequency of relapses Expectoration characteristics
• M/F = 117/64 ↓ to time of relapses, ↑ spirometric parameters
Mean age 62.5 years ↓ time of recovery  
Pidotimod activity against chronic bronchitis exacerbation 580 COPD ↓ fewer infectious exacerbations  
• Treatment group M/F = 94/31 mean age 66.2 years ↑ better response to antibiotics treatment  
↓days out of work
• Placebo treatment M/F = 200/63 mean age 65.2 years
Immunological function of T-lynphocyte in the elderly with chronic obstuctive pulmonary disease during acute exacerbations medication intervention 103 COPD ↓day of hospitalization ↑ the cell immune response in elderly patients
• Elderly COPD intervention group M/F = 23/9mean age 7.1 years ↓ cost of hospitalization
↑ spirometric parameters
• Elderly COPD control group M/F = 22/12 mean age 69.9 years
• Non elderly COPD control group M/F = 15/10 mean age 56.2 years
Ex vivo evaluation of Pidotimod activity in patients with chronic obstructive pulmonary disease. 52 COPD   ↑T-cells activity ↑stimulate macrophages and granulocytes
• Treatment group
M/F = 13/13 mean age 65.92
• Control group M/F = 10/16 mean age 62.46
Treatment of 30 cases of senile pneumonia with Pidotimod. 62 elderly with pneumonia ↓n° of recovery ↑ neutrophilic bactericidal
↑ bacterial eradication
↑ IgG level
• M/F = 33/29
• Mean age 72 years
Valutazione dell’attività del Pidotimod sulla secrezione di IgA in pazienti affetti da BPCO 20 COPD   ↑of secretory IgA in the sputum,
• From 40to 75 years
a stabilization of the level.
Valutazione sperimentale controllata dell’attività di Pidotimod in paziente affetti da BPCO 85 COPD ↓ number of exacerbations  
• M/F = 54/31
Pidotimod activity against chronic bronchitis exacerbations 580 COPD ↓number of infectious exacerbations  
• Treatment group M/F 94/31 mean age 66.2 years ↓duration of Exacerbations
↓duration of therapy
• Control group
M/F = 200/63 mean age 62.46 years
Naturally occurring immune response against bacteria commonly involved in upper respiratory tract infections: analysis of the antigen-specific salivary IgA levels. 21patients   ↑of the concentration of salivary IgA
• M/F = 12/10
• mean age 41 years
Treatment of 30 62 patients ↓ number of hospitalization ↑ neutrophilic activity
cases of senile pneumonia with Pidotimod • M/F = 33/29 ↑level of IgG
• Mean age 72 years
Pidotimod nel trattamento delle faringotonsilliti recidivanti 40 adults + children with recurrent pharingotonsillitis ↓ recurrent of upper respiratory ↑ of immune-response on Multitest
• M/F = 13/21
• Mean age 23.2 years